Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-161: Pembrolizumab in Advanced Melanoma
NCT03407170Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Primary completion
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, sponsored by Merck & Co.. Started Jun 2018; status: terminated.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03407170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407170.